Irene Ghobrial – författare

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma.

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma.Moving from the bench to the bedside to the forefront of therapeutic development, this source:helps clinicians and researchers effectively deploy therapeutic strategies into clinical practicereflects trends in the use of agents which target both the tumor cell and its bone marrow microenvironment to overcome resistance to conventional therapiesconsiders the critical role of the bone marrow microenvironment in the regulation of growth, survival, and homing of multiple myelomadiscusses novel therapies in phase I and phase II trials, focusing specifically on therapeutic options for patients with newly diagnosed or relapsed/refractory multiple myelomaaddresses novel therapies for other plasma cell disorders, and provides the framework for the design of next generation agents and combination therapiescovers the entire scope of translational work in multiple myeloma, from advances in molecular pathogenesis, to prognostic factors, immunotherapy, and new options for newly diagnosed and relapsed multiple myeloma patients